Sign in
CompletedNo phase

To Investigate the Effect of PEMF for Knee OA Patients

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
5 Jul 2022
Ended
31 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PEMF treatment
  • Placebo treatment
Record updated
6 May 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Primary osteoarthritis of knee
  • VAS score ≥ 4
  • Grade 2 and 3 osteoarthritis (Kellgren-Lawrence criteria)
  • No alleviation of symptoms after ≥ 3 months of nonsurgical treatment
  • No acute knee injuries in both limbs in the past 3 months
  • No muscle strain in both limbs in the past 3 months
  • Voluntarily agreed to participate and signed the informed consent form

Who cannot take part

  • Patient with a pacemaker, an implantable defibrillator, neurosurgical clips, a neurostimulator, cochlear implant, a stent, an insulin pump
  • Skin diseases around the target knee joint
  • Inflammatory joint disease (e.g., rheumatic inflammation)
  • Infectious joint disease (e.g., septic arthritis)
  • Severe pain in other areas affects the diagnosis of function and symptoms of knee joints
  • Injection in target knee within 3 months of enrolment
  • Pregnant or breastfeeding
  • Physical inability to undertake testing procedures
  • Inability to give informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Health care costs are increasing alarmingly, which will impose an overwhelming economic burden to an aging society like that of Hong Kong. For example, degenerative musculoskeletal disorders such as osteoarthritis (OA) present a grand challenge with its high prevalence (>40% in the elderly suffered from knee OA). Knee osteoarthritis (OA) is the most common form of arthritis, and around 2 million population worldwide suffer from this disorder. OA is a debilitating progressive disease with typical pathological progress such as cartilage degeneration, inflammation, joint width narrowing and developing osteophytes. The main system of knee OA is acute pain leading to loss of mobility. There is no effective treatment to cure or stop the progression of OA. For now, the main method is to alleviate the pain and symptoms, including control weight, exercise, physical treatment and intake of NSAIDs/ paracetamol.

Read full original descriptionShow less

Pulsed electromagnetic field (PEMF) treatment has shown to enhance cell activity related to tissue healing, delay bone and cartilage degeneration and give beneficial effects such as relief in pain, anti-inflammation and reduce swelling. In clinic, PEMF treatment has been reported to be safe, and has been proved to reduce the usage of NSAIDs and pain in patients with knee OA.

This study aims to investigate the effectiveness of PEMF therapy on for patients with knee OA.

The 2 groups in the trial

  • Mild-to-moderate Knee OA PEMF TreatmentTreatment being tested

    Patients with Mild-to-moderate Knee OA will accept PEMF treatment

    Treatment: PEMF treatment

  • Mild-to-moderate Knee OA Placebo TreatmentPlacebo, for comparison

    Patients with Mild-to-moderate Knee OA will accept placebo treatment

    Treatment: Placebo treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pulsed Electromagnetic Fields (PEMF) in Knee Osteoarthritis: a Double-blind, Placebo-controlled, Randomised Clinical Trial
Publications
Record updated
6 May 2025